Biopharmaceutical multinational Gilead Sciences has finalized the corporate acquisition of Tubulis GmbH, a privately held, Germany-based biotech entity operating at the clinical stage. The transactional structure is valued at up to $5 billion, comprising an immediate upfront cash consideration of $3.15 billion supplemented by up to $1.85 billion in contingent milestone allocations based on future developmental progress. Following the corporate integration, the specialized Tubulis team will maintain its baseline operations in Munich, Germany, forming the Tubulis ADC Innovation Center to anchor its decentralized discovery, manufacturing, and clinical functions.
The transaction is architected to incorporate next-generation antibody-drug conjugate (ADC) assets and technical platforms into Gilead’s expanding oncology franchise. Tubulis’ specialized technologies enable the design of distinct molecular architectures with improved biophysical traits, facilitating highly selective delivery of diverse payloads to malignant environments while maintaining robust on-tumor exposure for long-lasting therapeutic activity. The primary pipeline components acquired through the combination feature:
-
TUB-040: A NaPi2b-targeted ADC functioning as a topoisomerase-I inhibitor (TOPO1i), which has demonstrated encouraging clinical indications in managing platinum-resistant ovarian cancer profiles.
-
TUB-030: A 5T4-directed ADC candidate currently undergoing programmatic evaluation across a broad spectrum of solid tumor classifications.
Executive leadership at Gilead indicated that the definitive acquisition builds upon insights derived from a prior two-year operational collaboration, which generated strong conviction regarding Tubulis’ biological platforms and developmental team. By synthesizing Gilead’s established global infrastructure with Tubulis’ structural innovations in ADC design, the unified enterprise aims to accelerate the commercial deployment of advanced targeted options for some of the most clinically challenging malignancies worldwide.
Source: https://www.contractpharma.com/breaking-news/gilead-sciences-completes-acquisition-of-tubulis/